Earnings

LivaNova Publishes Results In Neuromodulation: Technology At The Neural Interface Regarding Its CORE-VNS Trial Of Its VNS Therapy Devices

Oct 23, 2026 · 09:06 AM ET· updated 2h ago

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS

Why It Matters

LivaNova shared long-term results from a study of its nerve-stimulation device. When companies publish good research data, it can boost trust in their products.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LIVN81.38

+0.11 (+0.13%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.